Evidence map›Paper›PMID 41160165›Full record

ReviewHerzschrittmachertherapie & Elektrophysiologie2026

[What to do with device-detected atrial fibrillation? : Executive summary of the position paper of the German Society of Cardiology].

Tobias Tönnis, Nina Becher, Ralf Birkemeyer, David Duncker, Lars Eckardt, Klaus Gröschel, Dominik Linz, Christian Meyer, Florian Straube, Arian Sultan and 3 more

Abstract readEnglish AbstractReview
In one paragraph

Review in Herzschrittmachertherapie & Elektrophysiologie, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Tobias TönnisKlinik für Kardiologie, Universitätsklinikum Hamburg-Eppendorf, Universitäres Herz- und Gefäßzentrum, Martinistraße 52, 20246, Hamburg, Deutschland. t.toennis@uke.de.
Nina BecherKlinik für Kardiologie, Universitätsklinikum Hamburg-Eppendorf, Universitäres Herz- und Gefäßzentrum, Martinistraße 52, 20246, Hamburg, Deutschland.
Ralf BirkemeyerHerzklinik Ulm, Ulm, Deutschland.
David DunckerHannover Herzrhythmus Centrum, Klinik für Kardiologie und Angiologie, Medizinische Hochschule Hannover, Hannover, Deutschland.
Lars EckardtKlinik für Kardiologie II, Universitätsklinikum Münster (UKM), Münster, Deutschland.
Klaus GröschelKlinik und Poliklinik für Neurologie, Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Mainz, Deutschland.
Dominik LinzMaastricht UMC Heart + Vascular Center Department of Cardiology, Maastricht, Niederlande.
Christian MeyerEvangelisches Krankenhaus Düsseldorf Klinik für Kardiologie, Düsseldorf, Deutschland.
Florian StraubeKlinik für Kardiologie und Internistische Intensivmedizin, München Klinik Bogenhausen, München, Deutschland.
Arian SultanAbteilung für Kardiologie, Asklepios Klinik St. Georg, Hamburg, Deutschland.
Rolf WachterUniversitätsklinikum Leipzig Klinik und Poliklinik für Kardiologie, Leipzig, Deutschland.
Maura ZyllaKardiologie, Angiologie u. Pneumologie, Universitätsklinikum Heidelberg Klinik für Innere Med. III, Heidelberg, Deutschland.
Paulus KirchhofKlinik für Kardiologie, Universitätsklinikum Hamburg-Eppendorf, Universitäres Herz- und Gefäßzentrum, Martinistraße 52, 20246, Hamburg, Deutschland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Device-detected atrial fibrillation (DDAF), like clinical atrial fibrillation (AF), is also associated with an increased risk of thromboembolic events, although the risk appears to be significantly lower. The efficacy and safety of oral anticoagulation in DDAF were investigated in two large randomized trials (NOAH-AFNET 6 and ARTESIA [13, 19]). They showed a low rate of ischemic strokes without anticoagulation (about 1% per year). This risk can still be reduced by therapeutic anticoagulation, but the risk of severe bleeding increases. In the recently published position paper [36] of the German Society of Cardiology, the current study situation was presented and expert recommendations were given on how to deal with DDAF.

Indexed as

AnticoagulantsAtrial FibrillationPractice Guidelines as TopicThromboembolismCardiologyGermanyHemorrhageHumansAnticoagulantsAnticoagulationAtrial fibrillationHeart and brainICDPacemaker

Identifiers

PMID41160165
PMCPMC12916953

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.